Palisade Bio, Inc. - PALI STOCK NEWS

Palisade Bio, Inc. announced the appointment of Margery Fischbein to its Board of Directors. Ms. Fischbein, a veteran in Wall Street and the biotech industry, brings expertise in corporate finance, business development, M&A, licensing, and strategic alliance transactions. Her appointment is expected to enhance Palisade Bio's strategy and pipeline of novel therapeutics, particularly in autoimmune, inflammatory, and fibrotic diseases.

Palisade Bio, Inc. (Nasdaq: PALI) closed a $4 million private placement with an institutional investor for 615,242 shares of common stock, intended for development of PALI-2108 and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent. The company issued unregistered warrants for up to 922,863 shares of common stock with a term of seven years and an exercise price of $6.314 per share.

Palisade Bio, a biopharmaceutical company, is raising $4 million through a private placement offering. The company will issue common stock and warrants to an institutional investor at $6.5015 per share. The net proceeds will be used for working capital and general corporate purposes. The closing is expected around May 6, 2024.

Palisade Bio announced the successful completion of an analysis demonstrating the potent anti-inflammatory effects of PALI-2108 in treating Ulcerative Colitis (UC). The study showed the superior efficacy of PALI-2108 compared to the approved PDE4 inhibitor apremilast, positioning it as a next-generation therapeutic option for inflammatory bowel disease. The company is set to begin Phase 1 human clinical trials before the end of the year, with promising results from the study conducted in collaboration with Paraza Pharma, Inc.

Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences to advance precision medicine for ulcerative colitis therapy. The partnership grants Palisade Bio access to advanced bioinformatics tools for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples to identify biomarkers for patient selection using machine learning. This collaboration marks a significant milestone in Palisade Bio's mission to redefine UC treatment through personalized therapies.

Palisade Bio successfully demonstrates bioactivation of PALI-2108 in an ex-vivo study of normal healthy and ulcerative colitis patients' stool, showing promising results for the treatment of ulcerative colitis.

Palisade Bio, Inc. (PALI) to present at the Virtual Investor Lunch Break event, featuring an overview by CEO J.D. Finley and CMO Dr. Mitch Jones. The live webcast on April 16, 2024, will focus on the company's business outlook and opportunities in autoimmune, inflammatory, and fibrotic diseases.

Palisade Bio, Inc. (Nasdaq: PALI) announces the advancement of PALI-2108, a treatment for moderate-to-severe ulcerative colitis, towards Phase 1 clinical study by the end of the year. The company presented at IBD Innovate, discussing the development, differentiation, and clinical pathway of PALI-2108.

Palisade Bio, Inc. (Nasdaq: PALI) announces a 1-for-15 reverse stock split to increase per share trading price and comply with Nasdaq listing requirements. The split will be effective on April 5, 2024, with trading under the symbol 'PALI' and new CUSIP number 696389402.